📣 VC round data is live. Check it out!
- Public Comps
- iNtRON Biotechnology
iNtRON Biotechnology Valuation Multiples
Discover revenue and EBITDA valuation multiples for iNtRON Biotechnology and similar public comparables like HAEMATO, Applied BioCode, Pangaea Oncology, Osang Healthcare and more.
iNtRON Biotechnology Overview
About iNtRON Biotechnology
iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business.
Founded
1999
HQ

Employees
N/A
Website
Financials (FY)
EV
$45M
Valuation Multiples
Start free trialiNtRON Biotechnology Financials
iNtRON Biotechnology reported last fiscal year revenue of $4M and negative EBITDA of ($5M).
In the same fiscal year, iNtRON Biotechnology generated $2M in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).
iNtRON Biotechnology P&L
In the most recent fiscal year, iNtRON Biotechnology reported revenue of $4M and EBITDA of ($5M).
iNtRON Biotechnology is unprofitable as of last fiscal year, with gross margin of 54%, EBITDA margin of (122%), and net margin of (156%).
Financial data powered by Morningstar, Inc.
iNtRON Biotechnology Stock Performance
iNtRON Biotechnology has current market cap of $72M, and enterprise value of $45M.
iNtRON Biotechnology's stock price is $2.32.
iNtRON Biotechnology has an EPS (earnings per share) of $-0.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45M | $72M | -0.4% | — | — | — | $-0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialiNtRON Biotechnology Valuation Multiples
iNtRON Biotechnology trades at 11.6x EV/Revenue multiple, and (9.5x) EV/EBITDA.
iNtRON Biotechnology Financial Valuation Multiples
As of May 10, 2026, iNtRON Biotechnology has market cap of $72M and EV of $45M.
iNtRON Biotechnology has a P/E ratio of (11.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified iNtRON Biotechnology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


iNtRON Biotechnology Margins & Growth Rates
In the most recent fiscal year, iNtRON Biotechnology reported gross margin of 54%, EBITDA margin of (122%), and net margin of (156%).
iNtRON Biotechnology Margins
iNtRON Biotechnology Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
iNtRON Biotechnology Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
iNtRON Biotechnology Competitors
iNtRON Biotechnology competitors include HAEMATO, Applied BioCode, Pangaea Oncology, Osang Healthcare, electroCore, 3D Medicines, 4basebio, Biohit, Anixa Biosciences and Abingdon Health.
Most iNtRON Biotechnology public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.2x | — | 3.1x | — | |||
| 3.8x | — | (12.6x) | — | |||
| 4.1x | — | (62.5x) | — | |||
| 0.9x | — | 10.5x | — | |||
| 1.7x | 1.5x | (6.2x) | (7.6x) | |||
| 0.8x | — | (2.2x) | — | |||
| 54.7x | — | (4.7x) | — | |||
| 2.1x | 2.0x | 9.7x | 10.0x | |||
This data is available for Pro users. Sign up to see all iNtRON Biotechnology competitors and their valuation data. Start Free Trial | ||||||
iNtRON Biotechnology Investment Activity
iNtRON Biotechnology has invested in 1 company to date.
Latest investment by iNtRON Biotechnology was on December 31st 2020. iNtRON Biotechnology invested in LISCure Biosciences in their $11M Series B round (EV/Revenue multiple of ).
Latest Investments by iNtRON Biotechnology
| Description | LISCure Biosciences engineers bacteria-mediated immunotherapies for tumors, degenerative neurological disorders, autoimmune conditions, and metabolic diseases from its South Korea base. The company advances seven drug pipelines and two health food pipelines targeting microbiome modulation for therapeutic effects. |
| HQ Country | |
| HQ City | Seoul |
| Deal Date | 31 Dec 2020 |
| Round | Series B |
| Raised | $11M |
| Investors | eBEST; EuBiologics Co., Ltd.; Hana Financial Group; Hana Securities; Hi Investment & Securities; Industrial Bank of Korea; iNtRON Biotechnology; KDB Capital; HLB BioStep; Korea Investment & Securities; LabGenomics |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all iNtRON Biotechnology investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout iNtRON Biotechnology
| When was iNtRON Biotechnology founded? | iNtRON Biotechnology was founded in 1999. |
| Where is iNtRON Biotechnology headquartered? | iNtRON Biotechnology is headquartered in South Korea. |
| Is iNtRON Biotechnology publicly listed? | Yes, iNtRON Biotechnology is a public company listed on Korea Exchange. |
| What is the stock symbol of iNtRON Biotechnology? | iNtRON Biotechnology trades under 048530 ticker. |
| When did iNtRON Biotechnology go public? | iNtRON Biotechnology went public in 2011. |
| Who are competitors of iNtRON Biotechnology? | iNtRON Biotechnology main competitors include HAEMATO, Applied BioCode, Pangaea Oncology, Osang Healthcare, electroCore, 3D Medicines, 4basebio, Biohit, Anixa Biosciences, Abingdon Health. |
| What is the current market cap of iNtRON Biotechnology? | iNtRON Biotechnology's current market cap is $72M. |
| What is the current revenue of iNtRON Biotechnology? | iNtRON Biotechnology's last fiscal year revenue is $4M. |
| What is the current EV/Revenue multiple of iNtRON Biotechnology? | Current revenue multiple of iNtRON Biotechnology is 11.6x. |
| Is iNtRON Biotechnology profitable? | No, iNtRON Biotechnology is not profitable. |
| How many companies iNtRON Biotechnology has acquired to date? | iNtRON Biotechnology hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies iNtRON Biotechnology has invested to date? | As of May 2026, iNtRON Biotechnology has invested in 1 company. |
| What was the last iNtRON Biotechnology investment? | On 31st December 2020 iNtRON Biotechnology invested in LISCure Biosciences, participating in a $11M Series B round, alongside eBEST, EuBiologics Co., Ltd., Hana Financial Group, Hana Securities, Hi Investment & Securities, Industrial Bank of Korea, KDB Capital, HLB BioStep, Korea Investment & Securities, and LabGenomics. |
| In what companies iNtRON Biotechnology invested in? | iNtRON Biotechnology invested in LISCure Biosciences. |
See public comps similar to iNtRON Biotechnology
Lists including iNtRON Biotechnology
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
